微生态制剂联合阿德福韦酯用于乙肝肝硬化临床效果评价

摘要

Objective To observe the probiotics combined with adefovir clinical effect in the treatment of hepatitis B cirrhosis.Methods125 cases in our hospital diagnosed with cirrhosis were randomly divided into two groups,al patients while performing liver treatment regimens were as folows: the observation group,probiotics combined with adefovir dipivoxil,control group,single administration of adefovir. Treatment effect was observed two programs. ResultsThe results found that after treatment,the observation group HBV DNA negative rate(73.8%)was significantly higher seroconversion rate (60.0%),serum total bilirubin,ALT proglumetacin decreased compared with before treatment,but the effect was excelent better in observation group than the control group,the incidence of adverse reactions were observed(4.6%)than the control group 11.7%),the difference was statisticaly significant(P< 0.05)among al indicators groups. Conclusion Probiotics combined with adefovir dipivoxil therapy compared with conventional therapy can improve efficacy and reduce adverse reactions,more safe and effective.%目的：观察微生态制剂联合阿德福韦酯在治疗乙肝肝硬化时的临床效果。方法将我院收治的125例确诊的肝硬化患者随机分为两组，所有患者在进行保肝治疗的同时分别按以下方案治疗：观察组，微生态制剂联合阿德福韦酯；对照组，单一给药阿德福韦酯。观察两组方案的治疗效果。结果治疗后发现，观察组乙肝病毒DNA转阴率（73.8%）高于对照组转阴率（60.0%）；血清总胆红素、丙谷转氨酶较治疗前均下降，但观察组效果优于对照组；观察组不良反应发生率（4.6%）低于对照组（11.7%），所有指标组间差异具有统计学意义（P<0.05）。结论微生态制剂联合阿德福韦酯的治疗方案能够较传统疗法提高疗效，降低不良反应，更加安全有效。